uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology. Uppsala University, Science for Life Laboratory, SciLifeLab. Univ Uppsala Hosp, Sect Hematol, Entrance 50, S-75185 Uppsala, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Science for Life Laboratory, SciLifeLab.
Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Statistics.
St Olavs Hosp, Dept Hematol, Trondheim, Norway; Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway.
Show others and affiliations
2016 (English)In: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 50, 95-103 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND AIMS: The simultaneous measurement of many proteins is now possible using multiplex assays. In this pilot study we investigated a total of 124 proteins in plasma from chronic myeloid leukemia (CML) patients with the purpose of identifying proteins that are differently expressed at diagnosis and after tyrosine kinase inhibitor (TKI) treatment initiation.

METHODS: Samples were taken from 14 CML patients at diagnosis and after three months of TKI treatment (imatinib or dasatinib). Samples were analyzed by Mesoscale Discovery, Myriad RBM MAP technology and Olink Proseek.

RESULTS: Multiple plasma proteins were differentially expressed before and after initiation of TKI therapy. Protein patterns demonstrated a possible shift towards Th1-immunity and reduced angiogenic stimuli. Further, some plasma proteins were identified that can be of potential interest to study further for biologic, prognostic or therapeutic significance such as E-selectin, uPAR, growth hormone and carbonic anhydrase IX.

CONCLUSIONS: Plasma proteomics seems feasible and useful in CML patients, both for studying patterns of protein expression and for identifying single proteins differentially expressed before and after treatment. Plasma proteomics may be useful to map disease activity and biological processes. Hence, plasma proteomics can be used to understand drug mechanisms and treatment responses in CML.

Place, publisher, year, edition, pages
2016. Vol. 50, 95-103 p.
Keyword [en]
Proteomics, Chronic myeloid leukemia, Tyrosine kinase inhibitor, Th1, Angiogenesis
National Category
Cancer and Oncology Hematology
Identifiers
URN: urn:nbn:se:uu:diva-310831DOI: 10.1016/j.leukres.2016.09.019ISI: 000388315500015PubMedID: 27710869OAI: oai:DiVA.org:uu-310831DiVA: diva2:1058034
Available from: 2016-12-20 Created: 2016-12-20 Last updated: 2016-12-22Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Söderlund, StinaChristiansson, LisaPersson, IngerSimonsson, BengtOlsson-Strömberg, UllaLoskog, Angelica
By organisation
HaematologyScience for Life Laboratory, SciLifeLabClinical ImmunologyDepartment of Statistics
In the same journal
Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis
Cancer and OncologyHematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 73 hits
ReferencesLink to record
Permanent link

Direct link